// App-Quantinova.ai

: Venous Thromboembolism Following Pegaspargase in Adults Receiving Antithrombin Supplementation: A Single Center Characterization of Risk Factors and an Assessment of Supplementation Practice

Researchers

Presenter

  • Craig W. Freyer

Principal Investigators

  • Alex Ganetsky

  • Mitchell E. Hughes

  • Tracy M. Krause

  • Colleen Timlin

  • Noelle V. Frey

  • Elizabeth O. Hexner

  • Alison W. Loren

  • James K. Mangan

  • Mary Ellen Martin

  • Shannon R. McCurdy

  • Alexander E. Perl

  • David L. Porter

  • Selina Luger

Medical Centers

  • Department of Urology, Hospital of the University of Pennsylvania, Philadelphia, PA

  • Department of Medicine, University of Pennsylvania, Philadelphia, PA

  • Division of Hematology-Oncology, Department of Medicine, University of Pennsylvania, Merion Station, PA

  • Abramson Cancer Center and the Division of Hematology and Oncology, Hospital of the University of Pennsylvania, Philadelphia, PA

  • Division of Hematology-Oncology/Department of Medicine, Perelman Center for Advanced Medicine, Philadelphia, PA

  • Division of Hematology/Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

  • Division of Hematology/Oncology, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

  • Cardiovascular (CVS)

Disease

  • Venous thrombosis

Biomarkers

  • Breakpoint Cluster Region

Drug/Treatment

  • Pegaspargase

  • Oncaspar

  • Enoxaparin

  • Enoxaparin sodium

Outcome

  • N/A

Study Design

  • Single Center

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved